Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) (ERICH)

August 31, 2017 updated by: Daniel Woo, University of Cincinnati
The purpose of this study is to find risk factors for hemorrhagic stroke, specifically intracerebral hemorrhage (ICH), among Caucasians, African Americans, and Hispanics.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

6000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Tucson, Arizona, United States, 85724
        • University of Arizona
    • California
      • Los Angeles, California, United States, 90033
        • University of Southern California
    • District of Columbia
      • Washington, D.C., District of Columbia, United States, 20007
        • Georgetown University
    • Florida
      • Miami, Florida, United States, 33136
        • University of Miami
      • Miami, Florida, United States, 33136
        • University of Miami - Biorepository
    • Georgia
      • Atlanta, Georgia, United States, 30303
        • Emory University
    • Illinois
      • Chicago, Illinois, United States, 60612
        • University of Illinois
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • University of Maryland
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital
    • New Mexico
      • Albuquerque, New Mexico, United States, 87131
        • University of New Mexico
    • New York
      • New York, New York, United States, 10032
        • Columbia University
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27157
        • Wake Forest University
    • Texas
      • Dallas, Texas, United States, 75390
        • University of Texas Southwestern Medical Center at Dallas
      • Houston, Texas, United States, 77030
        • University of Texas Medical School at Houston
      • San Antonio, Texas, United States, 78229
        • University of Texas Health Science Center at San Antonio

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Our purpose is to enroll 1000 cases of ICH among whites, 1000 cases of ICH among blacks, and 1000 cases of ICH among Hispanics.

3000 controls matched to cases by race/ethnicity, age (+/- 5 years), gender, and geographic location.

Description

Inclusion Criteria:

All cases must meet the following eligibility criteria:

  1. Age 18 years or greater, fulfillment of the criteria for intracerebral hemorrhage
  2. Resident for at least 6 months within 50 miles of the recruiting center
  3. No evidence of trauma, vascular malformation or aneurysm, or brain tumor as a cause of the hemorrhage
  4. Ability of the patient or legal representative to provide informed consent

Exclusion Criteria:

Exclusion Criteria:

  1. Malignancies leading to coagulopathy
  2. Hemorrhagic transformation of ischemic infarct
  3. Hemorrhage secondary to dural venous sinus thrombosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Cases
3000 Cases
Controls
3000 Controls

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Cincinnati

Collaborators

Massachusetts General Hospital
The University of Texas Health Science Center, Houston
University of Miami
University of Maryland
Georgetown University
Columbia University
National Institute of Neurological Disorders and Stroke (NINDS)
University of Illinois at Chicago
Emory University
Duke University
University of Southern California
University of California, San Francisco
University of Virginia
The University of Texas Health Science Center at San Antonio
University of Arizona
University of New Mexico
St. Luke's-Roosevelt Hospital Center
Wake Forest University
University of Texas, Southwestern Medical Center at Dallas

Investigators

  • Principal Investigator: Matthew Flaherty, MD, University of Cincinnati

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2010

Primary Completion (Actual)

July 31, 2017

Study Completion (Actual)

August 1, 2017

Study Registration Dates

First Submitted

September 14, 2010

First Submitted That Met QC Criteria

September 14, 2010

First Posted (Estimate)

September 16, 2010

Study Record Updates

Last Update Posted (Actual)

September 1, 2017

Last Update Submitted That Met QC Criteria

August 31, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1008059
  • R01NS069763-01 (Other Grant/Funding Number: NINDS)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intracerebral Hemorrhage

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe